Feb 22 2010
PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, today provided information in response to inquiries about Soft Tissue Calcification ("STC") and the Company's products.
“As previously announced, our all-natural supplements offer consumers a range of options for achieving and maintaining individual health and well-being. Our scientific formulations address universal concerns like lowering cholesterol and reducing coronary arterial calcium, a precursor to heart attack, stroke, and other cardiovascular diseases”
"As previously announced, our all-natural supplements offer consumers a range of options for achieving and maintaining individual health and well-being. Our scientific formulations address universal concerns like lowering cholesterol and reducing coronary arterial calcium, a precursor to heart attack, stroke, and other cardiovascular diseases," said John Stanton, PanGenex Chairman.
"STC, or plaque, exists in many soft tissue diseases. STC is thought to either cause disease or be a contributing risk factor. Many prescription drugs target the treatment of such risk factors (such as lowering levels of cholesterol, a risk factor in heart disease). PanGenex's products offer a natural alternative. The Company has also worked on developing proprietary molecules for the detection and treatment of STC," Stanton concluded.
Ten doctors on FDA panel reviewing Abbott heart device had financial ties with company